Program
cabazitaxel
Also written as “Cabazitaxel (XRP6258)”, “CABAZITAXEL (XRP6258)” and “Cabazitaxel”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Nervous System Neoplasms · Small Cell Lung Carcinoma · Stomach Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 190 open or running | phase 4since Jul 20, 2012 | Dec 28, 2006 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 2since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| Jina Pharmaceuticals | 11 open or running | phase 2since Mar 17, 2025 | Mar 17, 2025 | Dec 2026phase 2 · NCT06890832 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Dec 28, 2006.
- Dec 2, 2010Phase 3 study in Prostate Cancer MetastaticSanofi · NCT01254279 · 984 enrolled · Australia, Austria, Belgium and more
- Mar 3, 20112 phase 3 studies in Prostatic NeoplasmsSanofi · NCT01308580, NCT01308567
- Mar 22, 2011Phase 1 study in Prostatic NeoplasmsSanofi · NCT01324583 · 48 enrolled · Japan
- Dec 6, 20112 phase 2 studiesSanofi · NCT01497964, NCT01500720
- Feb 2, 2012Phase 1 study in NeoplasmsSanofi · NCT01527929 · 25 enrolled · Belgium, Italy, Netherlands and more
- Mar 30, 2012Phase 2 study in Prostatic NeoplasmsSanofi · NCT01576029 · 2 enrolled · Brazil
- Jul 20, 2012Phase 4 study in Prostatic NeoplasmsSanofi · NCT01649635 · 45 enrolled · Brazil
- Oct 29, 2012Phase 2 study in Prostate Cancer MetastaticSanofi · NCT01718353 · 63 enrolled · United States, Canada
- Dec 13, 2012Phase 2 study in Malignant Solid Tumor - Malignant Nervous System NeoplasmSanofi · NCT01751308 · 39 enrolled · United States, Canada
- Dec 17, 2012Phase 1 study in Advanced Solid TumorSanofi · NCT01755390 · 42 enrolled · France, Spain
- Feb 27, 2015Phase 2 study in Prostate Cancer MetastaticSanofi · NCT02379390 · 8 enrolled · United States, Canada
- Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more
- Nov 22, 2016Bristol-Myers Squibb's first study: phase 2 study in Prostatic NeoplasmsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02985957 · 351 enrolled · United States, Australia, Austria and more
- Mar 17, 2025Jina Pharmaceuticals's first study: phase 2 study in Metastatic Castration-resistant Prostate Cancer, MCRPCNew to Jina PharmaceuticalsJina Pharmaceuticals · NCT06890832 · 75 planned
Ahead
- Dec 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate Cancer, MCRPCJina Pharmaceuticals · NCT06890832
TargetBeta
“Tubulin inhibitor”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| Docetaxelrule | Sanofi | phase 4 | 199 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06890832Metastatic Castration-resistant Prostate Cancer, MCRPC | 2 | Not yet recruiting | Jina Pharmaceuticals | Dec 2026 | 75 |
| NCT02985957Prostatic Neoplasms · United States, Australia, Austria and more | 2 | Completed | Bristol-Myers Squibb | Apr 5, 2022 | 351 |
| NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more | 4 | Completed | Sanofi | Mar 27, 2019 | 255 |
| NCT02379390Prostate Cancer Metastatic · United States, Canada | 2 | Terminated | Sanofi | May 10, 2018 | 8 |
| NCT01755390Advanced Solid Tumor · France, Spain | 1 | Completed | Sanofi | Aug 2002 | 42 |
| NCT01751308Malignant Solid Tumor - Malignant Nervous System Neoplasm · United States, Canada | 2 | Completed | Sanofi | Jul 2015 | 39 |
| NCT01718353Prostate Cancer Metastatic · United States, Canada | 2 | Completed | Sanofi | Aug 2015 | 63 |
| NCT01649635Prostatic Neoplasms · Brazil | 4 | Completed | Sanofi | Jan 2014 | 45 |
| NCT01576029Prostatic Neoplasms · Brazil | 2 | Completed | Sanofi | Dec 2013 | 2 |
| NCT01527929Neoplasms · Belgium, Italy, Netherlands and more | 1 | Completed | Sanofi | Nov 2013 | 25 |
| NCT01500720Small Cell Lung Carcinoma · United States, Brazil, Canada and more | 2 | Completed | Sanofi | Apr 2014 | 179 |
| NCT01497964Stomach Neoplasms · Korea, Republic of | 2 | Completed | Sanofi | May 2013 | 16 |
| NCT01324583Prostatic Neoplasms · Japan | 1 | Completed | Sanofi | Nov 2014 | 48 |
| NCT01308580Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Aug 2015 | 1,200 |
| NCT01308567Prostatic Neoplasms · United States, Australia, Belarus and more | 3 | Completed | Sanofi | Sep 2015 | 1,168 |
| NCT01254279Prostate Cancer Metastatic · Australia, Austria, Belgium and more | 3 | Completed | Sanofi | Dec 2014 | 984 |
| NCT01140607Neoplasms · United States | 1 | Completed | Sanofi | Jul 2014 | 56 |
| NCT01087021Neoplasms · United States, Belgium, Denmark and more | 1 | Completed | Sanofi | Apr 2011 | 45 |
| NCT01001221Neoplasms · United States | 2 | Terminated | Sanofi | Oct 2011 | 19 |
| NCT00925743Solid Cancer · United States | 1 | Completed | Sanofi | Mar 2013 | 76 |
| NCT00417079Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Sep 2009 | 755 |
How it is read
Names in the registry
- “Cabazitaxel (XRP6258)”, 7 entries
- “CABAZITAXEL (XRP6258)”, 3 entries
- “Cabazitaxel”, 2 entries
- “cabazitaxel XRP6258”, 2 entries
- “Cabazitaxel XRP6258”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 12 studies
- Neoplasms, 4 studies
- Nervous System Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.